Aim: To compare the respective clinical and pathologic features of antimitochondrial antibodies-negative (AMA-negative) primary biliary cirrhosis (PBC) and cholestatic type drug-induced liver injury (DILI) for clinical differential diagnosis.

Patients And Methods: Clinical data from 23 patients with AMA-negative PBC and 39 patients with cholestatic type DILI, treated at our hospital between January 2013 and January 2024, were collected and retrospectively analyzed.

Results: The cholestatic type DILI group exhibited a higher incidence of malaise and abdominal pain compared with the AMA-negative PBC group. Alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, low-density lipoprotein cholesterol, globulin, immunoglobulin G, immunoglobulin M, and anti-gp210/anti-Sp100 antibodies were higher in the AMA-negative PBC group compared with the cholestatic type DILI group. There were differences in the stages of inflammation and fibrosis between the cholestatic type DILI group and the AMA-negative PBC group. Lymphocyte and plasma cell infiltration in the confluent areas was more pronounced in the AMA-negative PBC group, while monocyte infiltration was greater in the cholestatic type DILI group. In the small bile duct reaction, the positive rate was higher in the AMA-negative PBC group compared with the cholestatic DILI group. Conversely, the positive rate of D-PAS staining was greater in the cholestatic type DILI group than in the AMA-negative PBC group. All of these differences were statistically significant (P < 0.05).

Conclusions: Comparing the AMA-negative PBC with the cholestatic type DILI revealed differences in liver function, lipid profiles, immunoglobulins, autoantibodies, and hepatic histopathologic features. These distinctions facilitate the clinical differentiation between the 2 conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCG.0000000000002126DOI Listing

Publication Analysis

Top Keywords

cholestatic type
36
ama-negative pbc
32
type dili
28
dili group
24
pbc group
24
group
12
cholestatic
10
type
9
ama-negative
9
pbc
9

Similar Publications

Aim: To compare the respective clinical and pathologic features of antimitochondrial antibodies-negative (AMA-negative) primary biliary cirrhosis (PBC) and cholestatic type drug-induced liver injury (DILI) for clinical differential diagnosis.

Patients And Methods: Clinical data from 23 patients with AMA-negative PBC and 39 patients with cholestatic type DILI, treated at our hospital between January 2013 and January 2024, were collected and retrospectively analyzed.

Results: The cholestatic type DILI group exhibited a higher incidence of malaise and abdominal pain compared with the AMA-negative PBC group.

View Article and Find Full Text PDF

Background: Liver fibrosis is caused by chronic toxic or cholestatic liver injury. Fibrosis results from the recruitment of myeloid cells into the injured liver, the release of inflammatory and fibrogenic cytokines, and the activation of myofibroblasts, which secrete extracellular matrix, mostly collagen type I. Hepatic myofibroblasts originate from liver-resident mesenchymal cells, including HSCs and bone marrow-derived CD45+ collagen type I+ expressing fibrocytes.

View Article and Find Full Text PDF

A 12-year-old female, resident of western India, presented with a history of pruritus associated with jaundice for two months. On presentation, she had icterus with mild palpable hepatomegaly. Investigations revealed direct hyperbilirubinemia and elevated transaminases, while gamma-glutamyl transferase levels were normal.

View Article and Find Full Text PDF

Aims/hypothesis: Quinine, when administered intraduodenally to activate bitter-taste receptors, in a dose of 600 mg, stimulates glucagon-like peptide-1 (GLP-1) and insulin, slows gastric emptying and lowers postprandial glucose in healthy people, with consequent implications for the management of type 2 diabetes; the effect of quinine on energy intake is uncertain. We have investigated the dose-related effects of quinine on postprandial blood glucose levels and energy intake in people with type 2 diabetes.

Methods: Male participants with type 2 diabetes (age: 68±5 years; HbA: 49.

View Article and Find Full Text PDF

Objective: Cholestatic diseases are common and classified as benign or malignant based on their etiology. HALP is a unique nutritional immune marker that combines indicators of nutritional status, including hemoglobin and albumin, with immune function markers like lymphocyte and platelet counts. We investigated the HALP score's ability to differentiate between benign and malignant causes in extrahepatic cholestasis patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!